{
    "nct_id": "NCT06234397",
    "official_title": "A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Have a Histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy.\n* PD-L1 positive expression (Tumor Proportion Score ≥1% or Combined Positive Score ≥1).\n* Have at least one lesion, not previously irradiated that can be accurately measured per RECIST version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Age of 18 years or older (or country's legal age of majority if the legal age was >18 years)\n* Adequate Hematologic and liver function.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received prior therapy with an anti-4-1BB(CD137) agent.\n* Known active CNS metastases and/or carcinomatous meningitis.\n* Known additional malignancy that is progressing or has required active treatment.\n* History of chronic liver disease or evidence of hepatic cirrhosis.\n* History of severe toxicities associated with a prior immunotherapy.\n* Has ongoing or suspected autoimmune disease.\n* Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.",
    "miscellaneous_criteria": "Key"
}